ABOUT RECEPTOR LIFE SCIENCES

Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience.

OUR TECHNOLOGIES

Receptor's delivery technologies, used in both inhaled and oral FDA-approved prescription drug products, are a validated solution for the three main challenges of cannabinoid medicine: low absorption, poor bioavailability, and inconsistent dosing.

PIPELINE

Receptor Life Sciences is committed to developing our product candidates according to FDA standards. The approach for each product candidate is based on its scientific and medical rationale, a market analysis and feedback received from the FDA.

Our Team

Receptor Life Sciences has a team of dedicated leaders with decades of experience in research, drug delivery technologies, pre-clinical, clinical and commercialization of innovative therapies that fill unmet medical needs.

Mark Theeuwes

Mark is a healthcare executive with more than 20 years of experience. He has a wide range of focus both on the clinical and commercial sides of the business within the rare diseases, Neurology, urology, pain, primary care, infectious disease and dental industries. Most recently, Mark served as Executive Vice President and Chief Operating Officer of Engage Therapeutics. Engage Therapeutics was in the process of developing Staccato® Alprazolam and if approved will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study.

Previously, Mark served as Vice President of Sales, Trade and Commercial Operations at Egalet. As one of the first commercial employees, Mark was integral in establishing key functions within Trade, Commercial Operations and Sales Excellence at Egalet in order to lead the launch of three products within the company’s first two years. Prior to that, he was an Executive Director of Decision Support and member of the U.S. Commercial Leadership team at NPS until it was acquired by Shire plc in 2015. Before this role at NPS, Mark headed up Sales Operations at ViroPharma until it was acquired by Shire plc in 2014.

Mark started his career as a sales representative at Alza, which was acquired by Johnson & Johnson in 2001. Over the next 10 years, Mark held a number of sales, training, operations and analytics positions of increasing responsibility within the Johnson & Johnson family of companies.

Andrea Leone-Bay, Ph.D.

Dr. Leone-Bay is an internationally recognized authority on inhaled dry powder and oral drug delivery technologies. She brings unparalleled pharmaceutical development and formulation expertise with 48 publications in peer-reviewed journals and 93 issued U.S. patents.

Formerly Vice President and head of pharmaceutical development for MannKind Corporation, Dr. Leone-Bay has decades of drug development experience. Among her achievements are two FDA-approved and currently marketed products. She is an experienced R&D manager having led corporate divisions dedicated to research, development and commercialization of regulated drug products and drug-device combinations.

Traci Carman

Ms. Carman is an experienced finance and operations executive whose strategic insight and expertise led to the financial growth and scalable operations of numerous corporations, non-profits, and startups across a range of industries. Ms. Carman’s track record includes securing several successful funding rounds, IPO financial reporting, and structuring and closing multiple critical financings for startup companies. Ms. Carman has led and scaled all aspects of finance, accounting, tax, FP&A, treasury, risk management, debt and equity financing, and mergers and acquisions.

Kelly S. Kraft, Ph.D.

Kelly S. Kraft has over 20 years of pharmaceutical industry experience in oral and inhaled drug delivery. Dr. Kraft leads Receptor's product development team from basic research through manufacturing, testing, release, and stability of Phase 1 clinical supplies. She also oversees the conduct of nonclinical and clinical studies, coordinates work at external CDMOs, and aligns internal and external work with Receptor's regulatory partner.

Prior to Receptor, Dr. Kraft was the director of pharmaceutical R&D at MannKind Corporation, supporting AFREZZA® inhaled insulin and product line extensions including Treprostinil Technosphere inhalation powder.

After earning her Ph.D. in medicinal chemistry at the University of Georgia, Dr. Kraft began her career at Emisphere Technologies, focused on the development of oral absorption enhancers.

James B. Weissman

James B. Weissman, Executive Vice President and Chief Operating Officer, Dicerna Pharmaceuticals. Mr. Weissman has more than 30 years’ experience in the life sciences industry, with extensive international management experience in biotech and pharmaceutical general management, product development, licensing, business development, marketing and M&A activities. At Dicerna, Mr. Weissman leads alliance management, business development, corporate communications, corporate operations, and new product planning.

Prior to Dicerna, Mr. Weissman was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new products and strategic planning. Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing. In that position, he was responsible for the sales, profit and strategic targets for the company’s specialty products, including central nervous system, endocrinology, ophthalmology and oncology therapeutics and diversified portfolios.

Mark Theeuwes

Mark is a healthcare executive with more than 20 years of experience. He has a wide range of focus both on the clinical and commercial sides of the business within the rare diseases, Neurology, urology, pain, primary care, infectious disease and dental industries. Most recently, Mark served as Executive Vice President and Chief Operating Officer of Engage Therapeutics. Engage Therapeutics was in the process of developing Staccato® Alprazolam and if approved will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study.

Previously, Mark served as Vice President of Sales, Trade and Commercial Operations at Egalet. As one of the first commercial employees, Mark was integral in establishing key functions within Trade, Commercial Operations and Sales Excellence at Egalet in order to lead the launch of three products within the company’s first two years. Prior to that, he was an Executive Director of Decision Support and member of the U.S. Commercial Leadership team at NPS until it was acquired by Shire plc in 2015. Before this role at NPS, Mark headed up Sales Operations at ViroPharma until it was acquired by Shire plc in 2014.

Mark started his career as a sales representative at Alza, which was acquired by Johnson & Johnson in 2001. Over the next 10 years, Mark held a number of sales, training, operations and analytics positions of increasing responsibility within the Johnson & Johnson family of companies.

Orrin Devinsky, M.D., Ph.D

Dr. Devinsky directs the New York University (NYU) Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery. He is a Professor of Neurology, Neuroscience, Neurosurgery, and Psychiatry at NYU Grossman School of Medicine. He is a key member of several Scientific Advisory Boards across the pharmaceutical industry and for many disease organizations. Dr. Devinsky has published more than 600 articles and book chapters, has written or edited more than 20 books, and has been the principal investigator for multiple antiepileptic clinical trials. He has current research support from NINDS, NIMH, NIBIB, DoD, MURI, National Science Foundation and Simmons Foundation.

In the field of cutting-edge cannabinoid research, Dr. Devinsky was a principal investigator for the development of GW Pharmaceuticals' Epidiolex® (cannabidiol) to treat seizures associated with Dravet and Lennox-Gastaut syndromes, rare and severe forms of childhood-onset epilepsy. The work led Time magazine to name him one of the top 10 leaders advancing medical treatments in 2018.

Stephen J. Hoffman, M.D., Ph.D

Stephen J. Hoffman, M.D., Ph.D. is an independent consultant in the biotechnology and pharmaceuticals fields. He currently serves on the Board of Directors of AcelRx Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Apic-Bio, Inc., and Danforth Advisors.

Previously, Dr. Hoffman served as Chief Executive Officer and director of Aerpio Pharmaceuticals, Inc. from 2017 until 2019. Prior to that, he served as a senior advisor to PDL BioPharma, Inc. from 2014 until 2017. He was a managing director at Skyline Ventures from 2007 until 2014. From 2003 to 2007, Dr. Hoffman was a general partner at TVM Capital, a venture capital firm.

From 1994 to 2002, he served as President, Chief Executive Officer and a member of the Board of Directors of Allos Therapeutics, Inc., where he remained as Chairman of the Board of Directors until it was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. Dr. Hoffman also served on the Boards of Directors of Genocea Biosciences, Inc., and Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline in 2008.

Gregory T. Mayes, J.D.

Gregory T. Mayes, J.D. is an accomplished biopharma executive and an expert in biopharmaceutical business strategy and commercialization. He currently serves as President, CEO and Director of Antios Therapeutics, where he leads development of drugs that have the potential to serve as the backbone of a curative regimen for Hepatitis B ("HBV").

Prior to his role at Antios, Mr. Mayes in 2017 founded Engage Therapeutics. As CEO of Engage Mr. Mayes lead the development of an inhaled alprazolam for the rapid cessation of seizures. Engage recently completed a successful Phase II efficacy study enabling a competitive sale to Belgian pharmaceutical giant UCB.

Before founding Engage Mr. Mayes served as Chief Operating Officer and Board member of Advaxis Immunotherapies. In this position he was instrumental in establishing major pharma partnerships. He also developed a Phase III registration strategy and clinical development plan for Advaxis's lead product candidate, resulting in an FDA Fast Track Designation.

Prior to Advaxis, Mr. Mayes served as President and General Counsel and Board member for Unigene Laboratories. At Unigene he led out-licensing efforts for a novel oral peptide drug delivery platform. Mr. Mayes also served as Vice President, General Counsel, and Chief Compliance Officer at ImClone Systems, where he contributed significantly to the clinical development and commercialization of ERBITUX® (cetuximab). He was also instrumental to the $6.5 billion-dollar sale of ImClone Systems to Eli Lilly in 2008.

Mr. Mayes also served as Senior Counsel at AstraZeneca Pharmaceuticals LP, where he provided a wide range of legal services in connection with the development and commercialization of five approved products in AstraZeneca's oncology portfolio. Mr. Mayes is a cum laude graduate of Syracuse University where he was recognized as a Remembrance Scholar. He earned his J.D. degree magna cum laude from Temple University School of Law, where he was the Articles Editor on the Temple Law Review.

Gregory F. Wesner

Mr. Wesner is a leading intellectual property attorney and corporate growth strategist with decades of experience in pharmaceutical and life sciences companies. He has designed and implemented IP-driven strategies to power growth, financing, mergers and acquisitions, and public offerings.

Mr. Wesner identified the potential for immediate onset inhaled dry powder cannabinoid drugs, forging the exclusive Receptor-Mannkind global partnership. He also contributed to developing Receptor’s oral delivery technology that facilitates enhanced bioavailability of orally administered cannabinoid drugs. Receptor has adapted and patented its oral delivery technology for the global cannabinoid market.

Super Lawyer Washington Magazine has recognized Mr. Wesner yearly since 2007, and is recognized by Best Lawyers in America for his intellectual property expertise.

PRESS RELEASES